Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (46)

« Back to Publications

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.

Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15

Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy.

Armero M. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 455 - 464

Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Ng KW. et al, (2026), Nature, 649

Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development.

Navarrete M. et al, (2026), Annual review of medicine, 77, 239 - 251

Subclonal immune evasion in non-small cell lung cancer.

Dijkstra KK. et al, (2025), Cancer cell, 43, 1833 - 1849.e10

Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic.

Eguren-Santamaria I. et al, (2025), Journal for immunotherapy of cancer, 13

The Dark Side of NK Cells in Cancer Immunotherapy.

Galvez-Cancino F. et al, (2025), Cancer discovery, 15, 1777 - 1779

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Galvez-Cancino F. et al, (2025), Immunity, 58, 1862 - 1864

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies.

Galvez-Cancino F. et al, (2025), Immunity, 58, 1236 - 1253.e8

Clonal driver neoantigen loss under EGFR TKI and immune selection pressures.

Al Bakir M. et al, (2025), Nature, 639, 1052 - 1059

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.

Black JRM. et al, (2025), Nature medicine, 31, 70 - 76

MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.

Puttick C. et al, (2024), Nature genetics, 56, 2121 - 2131

Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.

Frankell AM. et al, (2024), Nature, 631

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.

Hobor S. et al, (2024), Nature communications, 15

Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models.

Hynds RE. et al, (2024), Nature communications, 15

Load More